Dr. Nagle on Investigational Cellular Therapies in Multiple Myeloma

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

There are several emerging cellular therapies in the multiple myeloma space, which are expected to receive regulatory approval within the next year. The first is idecabtagene vicleucel (ide-cel; bb2121), which targets BCMA, Nagle says.

Next, there is JNJ-4528, an investigational, BCMA-directed CAR T-cell product which is currently being evaluated in the CARTITUDE-1 study for the treatment of patients with relapsed/refractory multiple myeloma. This product has shown very encouraging results thus far, Nagle says.

Notably, despite the host of BCMA-targeted agents that are currently under exploration, there is an increasing interest in discovering new targets, especially for patients who relapse after BCMA-directed therapies, Nagle concludes.